Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Eliquis

Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Eliquis

Pfizer Laboratories (Pty) Ltd, in agreement with South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the following changes to the Professional Information of Eliquis (apixaban).

2019 Sep

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance